Published in Proc Natl Acad Sci U S A on June 23, 2014
Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A (2014) 1.51
Advancing the understanding of autism disease mechanisms through genetics. Nat Med (2016) 1.45
Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science (2015) 1.05
PTP1B inhibition suggests a therapeutic strategy for Rett syndrome. J Clin Invest (2015) 0.84
Developmental Dynamics of Rett Syndrome. Neural Plast (2016) 0.82
MeCP2 Affects Skeletal Muscle Growth and Morphology through Non Cell-Autonomous Mechanisms. PLoS One (2015) 0.81
Regulation of IGF -1 signaling by microRNAs. Front Genet (2015) 0.81
Loss of MeCP2 in cholinergic neurons causes part of RTT-like phenotypes via α7 receptor in hippocampus. Cell Res (2016) 0.79
Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome. Proc Natl Acad Sci U S A (2016) 0.76
Neurodevelopmental disorders: righting Rett syndrome with IGF1. Nat Rev Drug Discov (2014) 0.76
Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice. Elife (2016) 0.75
Insulin-like growth factors and their potential role in cardiac epigenetics. J Cell Mol Med (2016) 0.75
Lack of β2-AR Increases Anxiety-Like Behaviors and Rewarding Properties of Cocaine. Front Behav Neurosci (2017) 0.75
Cognition and mood-related behaviors in L3mbtl1 null mutant mice. PLoS One (2015) 0.75
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet (1999) 22.84
A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet (2001) 9.82
The story of Rett syndrome: from clinic to neurobiology. Neuron (2007) 8.08
A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell (2010) 7.51
The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron (2006) 4.74
Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol (2010) 4.03
Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci (2007) 3.81
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A (2009) 3.23
Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell (2011) 2.99
Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci (2005) 2.20
Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome. Neuroscience (2007) 1.88
Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci (2007) 1.85
Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell (2013) 1.80
Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc Natl Acad Sci U S A (2009) 1.79
Breathing dysfunctions associated with impaired control of postinspiratory activity in Mecp2-/y knockout mice. J Physiol (2007) 1.73
Quantitative autoradiography of beta 1- and beta 2-adrenergic receptors in rat brain. Proc Natl Acad Sci U S A (1984) 1.70
Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech (2012) 1.66
Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron (2010) 1.52
Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A (2014) 1.51
Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A (2014) 1.40
Epilepsy and the natural history of Rett syndrome. Neurology (2010) 1.40
An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model. PLoS One (2012) 1.40
Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. J Neurosci (2009) 1.36
Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. J Neurochem (2004) 1.33
Genome-wide analysis reveals methyl-CpG-binding protein 2-dependent regulation of microRNAs in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A (2010) 1.33
Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome--Mecp2 gene dosage effects and BDNF expression. Eur J Neurosci (2008) 1.29
Reduction of biogenic amine levels in the Rett syndrome. N Engl J Med (1985) 1.26
Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. Hum Mol Genet (2012) 1.23
Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci (2007) 1.23
The Emerging Role of microRNAs in Schizophrenia and Autism Spectrum Disorders. Front Psychiatry (2012) 1.22
MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-mediated repression and increases TRKB production. Epigenetics (2007) 1.20
Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav Pharmacol (2008) 1.18
Dual regulation of miRNA biogenesis generates target specificity in neurotrophin-induced protein synthesis. Cell (2012) 1.15
Defect in normal developmental increase of the brain biogenic amine concentrations in the mecp2-null mouse. Neurosci Lett (2005) 1.13
Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet (2014) 1.10
Separate respiratory phenotypes in methyl-CpG-binding protein 2 (Mecp2) deficient mice. Pediatr Res (2006) 1.07
The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome. Brain Dev (2001) 1.06
Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome. Sci Transl Med (2011) 1.04
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients. Autism Res Treat (2012) 0.97
Cerebellar and cerebral abnormalities in Rett syndrome: a quantitative MR analysis. AJR Am J Roentgenol (1992) 0.97
Clenbuterol induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage. Eur J Pharmacol (1999) 0.93
Beta2 adrenergic agonist, clenbuterol, enhances working memory performance in aging animals. Neurobiol Aging (2007) 0.93
Epac-mediated cAMP-signalling in the mouse model of Rett Syndrome. Neuropharmacology (2011) 0.91
Mechanisms and therapeutic challenges in autism spectrum disorders: insights from Rett syndrome. Curr Opin Neurol (2013) 0.90
Effects of postnatal dietary choline supplementation on motor regional brain volume and growth factor expression in a mouse model of Rett syndrome. Brain Res (2008) 0.89
Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.87
A review of the respiratory disorder in the Rett syndrome. Brain Dev (1992) 0.87
Activation of β2-adrenoceptor enhances synaptic potentiation and behavioral memory via cAMP-PKA signaling in the medial prefrontal cortex of rats. Learn Mem (2013) 0.87
Cholinergic hypofunction in MeCP2-308 mice: beneficial neurobehavioural effects of neonatal choline supplementation. Behav Brain Res (2011) 0.84
Recent Progress in Rett Syndrome and MeCP2 Dysfunction: Assessment of Potential Treatment Options. Future Neurol (2013) 0.84
Clenbuterol upregulates histone demethylase JHDM2a via the β2-adrenoceptor/cAMP/PKA/p-CREB signaling pathway. Cell Signal (2012) 0.82
Peripheral mediation of effects of clenbuterol on locomotor and investigatory behavior in rats. Pharmacol Biochem Behav (1988) 0.80
The β2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity. Brain Behav Immun (2010) 0.80
A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst Abus (2013) 0.78
Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A (2014) 1.51